Key result
Drug repurposing provides a faster and cheaper path to viral treatments than de novo discovery.
Why the study?
Emerging and re-emerging viral infections lacking effective treatments and with rising drug resistance pose a major global health threat, making faster and more affordable countermeasure development through drug repurposing urgently needed.
Drug repurposing offers a faster and more affordable strategy compared to de novo drug discovery for developing countermeasures against viral infections.
Supports accelerated antiviral responses via repurposing; leaves open prospective trials to confirm clinical utility.
In recent years, the emergence of new viruses and the re-emergence of old ones have posed a significant challenge to global Public Health. Viruses characterised by high morbidity and mortality rates have the potential to spread rapidly, causing large epidemic outbreaks and even pandemics. In this context, viral infections still lacking effective treatments represent a serious threat to human health. For this reason, sustained development and implementation of countermeasures are urgently needed against these infections, as they are for diseases for which the emergence of drug resistance is rapidly increasing. In this regard, compared to de novo drug discovery, drug repurposing could represent a highly efficient, faster, and more affordable strategy to develop new drugs. Here, we provide a comprehensive review of the different experimental and computational approaches used for drug repurposing and discuss their advantages and limitations in comparison with other drug discovery strategies. In addition, as an example of the successful application of drug repurposing, we present the case of approved antifungal drugs that could be repurposed to counteract viral infections.
No takes yet. Share an insight, caveat, or question.
Tuci et al. (2025) conducted a review in Viral infections. Drug repurposing (antifungal drugs) vs. De novo drug discovery was evaluated. Drug repurposing, such as using approved antifungal drugs, represents a highly efficient, faster, and more affordable strategy to develop new treatments for viral infections compared to de novo discovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: